Cargando…

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA

PURPOSE: We recently reported the development of a cell-free DNA (cfDNA) targeted methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test that includes cancer signal origin prediction. Here, we evaluated the prognostic significance of cancer detection by the MCED te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaoji, Dong, Zhao, Hubbell, Earl, Kurtzman, Kathryn N., Oxnard, Geoffrey R., Venn, Oliver, Melton, Collin, Clarke, Christina A., Shaknovich, Rita, Ma, Ting, Meixiong, Gerry, Seiden, Michael V., Klein, Eric A., Fung, Eric T., Liu, Minetta C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401481/ https://www.ncbi.nlm.nih.gov/pubmed/34088722 http://dx.doi.org/10.1158/1078-0432.CCR-21-0417

Ejemplares similares

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
por: Hu, Chunling, et al.
Publicado: (2022)

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
por: Leung, Eric, et al.
Publicado: (2021)

Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years
por: Plym, Anna, et al.
Publicado: (2022)

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
por: Abbott, Charles W., et al.
Publicado: (2021)

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
por: Leman, Raphaël, et al.
Publicado: (2023)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
por: Nadauld, Lincoln D., et al.
Publicado: (2021)

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Stolarova, Lenka, et al.
Publicado: (2023)

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
por: Williams, Christopher J.M., et al.
Publicado: (2023)

95233 Analysis of 5'UTR Variation in Rare Disease Patients Reveals Variants of Potential Disease Relevance
por: Bowles, Bradley, et al.
Publicado: (2021)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
por: Larkin, James R., et al.
Publicado: (2022)

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
por: Fitzpatrick, Amanda, et al.
Publicado: (2022)

Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
por: Thorat, Mangesh A., et al.
Publicado: (2021)

Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC
por: Sahaf, Bita, et al.
Publicado: (2021)

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
por: Damrauer, Jeffrey S., et al.
Publicado: (2021)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
por: Sharma, Sai Kiran, et al.
Publicado: (2022)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
por: Marisa, Laetitia, et al.
Publicado: (2021)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022)

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
por: Li, Shuo, et al.
Publicado: (2022)

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
por: Madanat-Harjuoja, Laura M., et al.
Publicado: (2022)

Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands
por: Kwon, Daniel, et al.
Publicado: (2022)

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
por: Hoes, Louisa R., et al.
Publicado: (2022)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
por: Henriksen, Tenna Vesterman, et al.
Publicado: (2022)

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
por: Liyasova, Mariya, et al.
Publicado: (2021)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization
por: Sastre-Garau, Xavier, et al.
Publicado: (2021)

Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
por: Bleach, Rachel, et al.
Publicado: (2021)

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
por: Jeannot, Emmanuelle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ph5rkn6q4iauhd59p4d5286j0b